Related Experiment Video
Updated: Mar 25, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
Antifibrotic Therapies: Where Are We Now?
Young Joon Yoon1, Scott L Friedman1, Youngmin A Lee1
1Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.
Seminars in Liver Disease
|February 13, 2016
Summary
Fibrosis, a common tissue repair response, shares core mechanisms across organs. Novel antifibrotic therapies and noninvasive assessment methods are emerging for liver fibrosis, offering new treatment possibilities.
Area of Science:
- Fibrosis research
- Translational medicine
- Drug development
Background:
- Fibrosis is a universal tissue repair response to injury.
- Common fibrotic pathways exist across organs like the kidney, lung, skin, and liver.
- Organ-specific pathways also contribute to fibrosis development.
Purpose of the Study:
- To review the mechanisms of liver fibrosis.
- To outline potential therapeutic targets for liver fibrosis.
- To discuss antifibrotic therapies in preclinical and clinical trials.
Main Methods:
- Review of existing literature on fibrosis mechanisms.
- Identification of common and specific fibrotic pathways.
- Analysis of current preclinical and clinical antifibrotic drug development.
Main Results:
- Shared core pathways offer cross-tissue antifibrotic strategies.
- Numerous small molecules and biologics are in clinical trials for fibrotic diseases.
- Noninvasive fibrosis assessment methods are crucial for clinical trials.
Conclusions:
- Antifibrotic options for liver fibrosis are becoming a reality.
- Drug repurposing and combination therapies are accelerating development.
- Novel noninvasive assessment tools are needed for clinical trial endpoints.
Related Concept Videos
01:30Heart Failure V: Medical Management
512
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:22Heart Failure VI: Adjunct Therapies
537
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
633
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633